Chemistry:Ercanetide
From HandWiki
Ercanetide (INN;[1] developmental code name NNZ-2591) is a synthetic analog of cyclic glycine-proline (cGP) and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome,[2][3] and Prader-Willi syndrome.[4]
See also
- Traneurocin (NA-831)
References
- ↑ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf [bare URL PDF]
- ↑ Markati, Theodora; Duis, Jessica; Servais, Laurent (3 July 2021). "Therapies in preclinical and clinical development for Angelman syndrome". Expert Opinion on Investigational Drugs 30 (7): 709–720. doi:10.1080/13543784.2021.1939674. PMID 34112038.
- ↑ Heussler, Helen S. (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome". Current Opinion in Psychiatry 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. ISSN 0951-7367. PMID 33395098. https://journals.lww.com/co-psychiatry/abstract/2021/03000/emerging_therapies_and_challenges_for_individuals.9.aspx.
- ↑ "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614". https://clinicaltrials.gov/study/NCT05879614.
 |  |
